SELECT id, `name`, primary_key, `key`, treemapgroup, name_cn, zacks_table_name, compare_key, compare_display_name from gurufocu_main.financial_definition where termpagedisplay=1 and `key` = 'total_buyback_3y' Zealand Pharma A/S Financial Dictionary(OCSE:ZEAL)
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OCSE:ZEAL) » Definitions

Zealand Pharma A/S


View and export this data going back to 2010. Start your Free Trial

Zealand Pharma A/S Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OCSE:ZEAL) » Definitions
Comparable Companies
OCSE:ALK B OCSE:BAVA OCSE:GUBRA OCSE:PEG A OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX BGNE SZSE:300122 ALNY OCSE:GMAB XKRX:068270 BMRN
Traded in Other Exchanges
ZLDPF:USA ZEALc:UK 0NZU:UK 22Z:Germany
Address
Sydmarken 11, Soborg, DNK, DK-2860
Website
https://www.zealandpharma.com
Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.